immunology

Numero quattro: Immunology experts at deal-focused IFM line up $55.5M for the next leg of their drug exploration journey
Numero quattro: Immunology experts at deal-focused IFM line up $55.5M for the next leg of their drug exploration journey
Endpoints
IFM Therapeutics
immunology
Atlas Ventures
Flag link:
Lilly counts on growing markets to boost lagging Taltz, Trulicity
Lilly counts on growing markets to boost lagging Taltz, Trulicity
Fierce Pharma
Eli Lilly
Trulicity
Taltz
immunology
type 2 diabetes
Flag link:
AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira
AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira
Motley Fool
AbbVie
Rinvoq
Humira
immunology
Flag link:
5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report
5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report
Yahoo/Motley Fool
JNJ
earnings
immunology
devices
Flag link:
Sanofi Cuts a Whopping 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases
Sanofi Cuts a Whopping 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases
BioSpace
Sanofi
Rare Diseases
immunology
cancer
R&D
Flag link:
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis
Fierce Pharma
JNJ
JPMHC 2019
immunology
psoriasis
Tremfya
Flag link:
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Forget Remicade -- Here's How Johnson & Johnson Plans to Grow
Motley Fool
JNJ
Stelara
Zytiga
Darzalex
oncology
immunology
Flag link:
ABBV to Focus on Advancing Late-Stage Immunology Research in 2018
ABBV to Focus on Advancing Late-Stage Immunology Research in 2018
Market Realist
AbbVie
R&D
immunology
Upadacitinib
risankizumab
Flag link:
Eli Lilly, sporting a lower tax rate, scouts smaller deals in immunology, cancer
Eli Lilly, sporting a lower tax rate, scouts smaller deals in immunology, cancer
Fierce Pharma
Eli Lilly
M&A
immunology
Flag link:
Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint
Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint
Endpoints
Charles River Laboratories
KWS BioTest
M&A
immunology
R&D
Flag link:
King cancer: The top 10 therapeutic areas in biopharma R&D
King cancer: The top 10 therapeutic areas in biopharma R&D
Endpoints
R&D
cancer
neurology
infection
immunology
cardiovascular disease
diabetes
Flag link:
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
U.S. prosecutors zero in on J&J marketing, targeting top immunology, hep C meds
Fierce Pharma
JNJ
drug manufacturing
immunology
hepatitis C
Remicade
Simponi
Stelara
Olysio
Flag link:
Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results
Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results
TheStreet.com
JNJ
earnings
immunology
diabetes
Flag link:
Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents
Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine’s Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents
Yahoo
Bristol-Myers Squibb
Foundation Medicine
R&D
tumors
immunology
Flag link:
Johnson & Johnson's Immunology Pipeline Is Golden
Johnson & Johnson's Immunology Pipeline Is Golden
Seeking Alpha
JNJ
immunology
Stelara
sirukumab
CNTO 6785
Flag link: